These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 38196277

  • 1. Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.
    Li Y, Liu W, Chen J, Chen Y, Guo J, Pang H, Zhang W, An C, Li C.
    Cancer Med; 2024 Jan; 13(1):e6836. PubMed ID: 38196277
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S, Xu Y, Mao Y, He M, Chen Z, Huang S, Li D, Lv Y, Wu J.
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
    Xiao Y, Deng W, Luo L, Zhu G, Xie J, Liu Y, Wan R, Wen W, Hu Z, Shan R.
    BMC Cancer; 2024 May 14; 24(1):588. PubMed ID: 38745113
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy(HAIC) Combined with PD-1 Inhibitors for Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Multicenter Propensity Score Matching Analysis.
    Zhang F, Zhong S, Wei Q, Zhang H, Hu H, Zeng B, Zheng X.
    J Hepatocell Carcinoma; 2024 May 14; 11():1961-1978. PubMed ID: 39429914
    [Abstract] [Full Text] [Related]

  • 9. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    An C, Fu Y, Li W, Zuo M, Wu P.
    Cancer; 2023 Jul 15; 129(14):2235-2244. PubMed ID: 37029486
    [Abstract] [Full Text] [Related]

  • 10. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ, Lai ZC, He MK, Bu XY, Chen HW, Zhou YM, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Shi M, Li QJ.
    Technol Cancer Res Treat; 2021 Jul 15; 20():15330338211063848. PubMed ID: 34898313
    [Abstract] [Full Text] [Related]

  • 11. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Wang Z, Lin D, Luo T.
    Ann Surg Oncol; 2024 Nov 15; 31(12):7860-7869. PubMed ID: 39090499
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
    Fukubayashi K, Tanaka M, Izumi K, Watanabe T, Fujie S, Kawasaki T, Yoshimaru Y, Tateyama M, Setoyama H, Naoe H, Kikuchi K, Sasaki Y.
    Cancer Med; 2015 Aug 15; 4(8):1214-23. PubMed ID: 26044168
    [Abstract] [Full Text] [Related]

  • 13. Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma.
    Zuo M, Cao Y, Yang Y, Zheng G, Li D, Shao H, Ma Q, Song P, An C, Li W.
    Hepatol Int; 2024 Oct 15; 18(5):1486-1498. PubMed ID: 38961006
    [Abstract] [Full Text] [Related]

  • 14. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
    Pang B, Zuo B, Huang L, You X, Liu T, Hao J, Yuan C, Yang C, Yee Lau W, Zhang Y.
    Int Immunopharmacol; 2024 Aug 20; 137():112492. PubMed ID: 38906005
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis.
    Yang M, Jiang X, Liu H, Zhang Q, Li J, Shao L, Zhao L.
    Front Pharmacol; 2024 Aug 20; 15():1410767. PubMed ID: 39144625
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, Deng HJ, He M, Mu LW, Zhao M.
    J Clin Oncol; 2022 Feb 10; 40(5):468-480. PubMed ID: 34905388
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.
    Li R, Wang X, Li H, Wang M, Wang J, Wang W, Zhou Q.
    J Hepatocell Carcinoma; 2024 Feb 10; 11():1727-1740. PubMed ID: 39281003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.